143 related articles for article (PubMed ID: 10647666)
1. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
Merrill RM; Stephenson RA
J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
[TBL] [Abstract][Full Text] [Related]
2. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Brenner H; Arndt V
J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
[TBL] [Abstract][Full Text] [Related]
4. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening.
Gilliland F; Becker TM; Smith A; Key CR; Samet JM
Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):105-11. PubMed ID: 8049631
[TBL] [Abstract][Full Text] [Related]
5. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
[TBL] [Abstract][Full Text] [Related]
6. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
8. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
[TBL] [Abstract][Full Text] [Related]
9. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
10. Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates.
Di Matteo L; Di Matteo R
Eur J Health Econ; 2005 Dec; 6(4):298-308. PubMed ID: 16180027
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
12. Decrease in prostate cancer incidence and mortality in Germany - effects of opportunistic PSA screening or more?
Rohde V; Weidner W; Katalinic A
Urol Int; 2009; 83(2):134-40. PubMed ID: 19752605
[TBL] [Abstract][Full Text] [Related]
13. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
14. Impact of screening on prostate cancer rates and trends.
Mettlin C
Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
[TBL] [Abstract][Full Text] [Related]
15. Mortality in prostate cancer.
Krongrad A; Lai H; Lamm SH; Lai S
J Urol; 1996 Sep; 156(3):1084-91. PubMed ID: 8709313
[TBL] [Abstract][Full Text] [Related]
16. Quebec prostate cancer mortality dropped in 1996.
Meyer F; Moore L; Bairati I; Fradet Y
Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
[TBL] [Abstract][Full Text] [Related]
17. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
Feuer EJ; Mariotto A; Merrill R
Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
[TBL] [Abstract][Full Text] [Related]
18. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource.
Datta MW; Dhir R; Dobbin K; Bosland MC; Melamed J; Becich MJ; Orenstein JM; Kajdacsy-Balla AA; Patel A; Macias V; Berman JJ
J Urol; 2005 May; 173(5):1546-51. PubMed ID: 15821483
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
